ScholarIQanswers from OpenAlex
University of Ulsan
InstitutionResearch output, impact & collaborations
University of Ulsan is a institution indexed in ScholarIQ from OpenAlex.
What is known about University of Ulsan?
ScholarIQrecord summary
University of Ulsan is a research organisation in Ulsan, KR. OpenAlex records 64,840 works and 5,718,868 citations for it. 16,121 researchers list it as their most recent affiliation.
How many works does University of Ulsan have?
ScholarIQindexed works
University of Ulsan has 64,840 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does University of Ulsan have?
ScholarIQcitation count
University of Ulsan has 5,718,868 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at University of Ulsan?
ScholarIQresearcher count
University of Ulsan has 16,121 researchers in the ScholarIQ index.
What is the average h-index at University of Ulsan?
ScholarIQavg h-index
University of Ulsan has an average h-index of 49.6 in OpenAlex.
What is the ROR of University of Ulsan?
ScholarIQror
The ROR for University of Ulsan is on the source record.
What is the OpenAlex record for University of Ulsan?
ScholarIQopenalex
The OpenAlex for University of Ulsan is on the source record.
What is the Wikidata of University of Ulsan?
ScholarIQwikidata
The Wikidata for University of Ulsan is on the source record.
Who are the most-cited researchers behind University of Ulsan?
ScholarIQtop researchers by citations
What are the most-cited papers on University of Ulsan?
ScholarIQmost cited works
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabe Caro, Bogdan Żurawski, Sang‐We Kim, Enric Carcereny, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez, Hiroshi Sakai, István Albert, A. Vergnenègre, Solange Peters, Konstantinos Syrigos, Fabrice Barlési, Martin Reck, Hossein Borghaei, Julie R. Brahmer, Kenneth J. O’Byrne, William J. Geese, Prabhu Bhagavatheeswaran, Sridhar K. Rabindran, Ravi S. Kasinathan, Faith E. Nathan, Suresh S. Ramalingam
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, María Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil‐Gil, Wěi Li, Jean‐Yves Pierga, Seock‐Ah Im, Halle C. F. Moore, Hope S. Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung‐Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David Cameron
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger, Makoto Tahara, Lori J. Wirth, Bruce Robinson, Marcia S. Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H. Shah, Ana O. Hoff, Andrew G. Gianoukakis, Naomi Kiyota, Matthew H. Taylor, Sung‐Bae Kim, Monika K. Krzyzanowska, Corina E. Dutcus, Begoña de las Heras, Junming Zhu, Steven I. Sherman
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young‐Hyuck Im, Eun Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock‐Ah Im, Byeong‐Woo Park, Sung‐Bae Kim, Yasuhiro Yanagita, Shinji Ohno, Shintaro Takao, Kenjiro Aogi, Hiroji Iwata, Joon Jeong, Aeree Kim, Kyong Hwa Park, Hironobu Sasano, Yasuo Ohashi, Masakazu Toi
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
Yi‐Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lü, Kye Young Lee, Charuwan Akewanlop, Chong‐Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S. Herbst
How much of the research on University of Ulsan is open access?
ScholarIQopen access share
75%OPEN ACCESS